Statistics from Altmetric.com
Cardiovascular disease (CVD) is a major health problem globally. Many of the traditionally recognised risk factors contributing to adverse outcomes in these patients are managed in secondary prevention models. Obstructive sleep apnoea (OSA), a common condition in such patients,1 has been largely neglected. The first-line treatment of OSA is nasal continuous positive airway pressure (CPAP) treatment, which reduces daytime sleepiness and improves quality of life.2 However, the majority of individuals with CVD and concomitant OSA do not report daytime sleepiness. Until recently, there was a lack of long-term prospective randomised controlled trials (RCTs) addressing whether CPAP should be prescribed to non-sleepy …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.